New combo therapy aims to control advanced lung cancer
NCT ID NCT07637448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two types of drugs (EGFR-TKIs and a PD-1 antibody) can help control advanced non-small cell lung cancer with specific EGFR mutations. It involves 32 adults who have not had prior treatment. The main goal is to see how long the cancer stays under control before it progresses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR ACTIVATING MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Southern Medical University Nanfang Hospital Department of Oncology
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
- New PET scan could predict who benefits from targeted lung cancer therapy
- Lung cancer Drug's journey through the body tracked in tiny trial
- New drug cocktail targets Hard-to-Treat lung cancer with liver metastases
- Can a volunteer buddy help lung cancer patients feel better?